In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 6, Issue 5, 2010, Pages 662-671

  Semete, Boitumelo ^a   Booysen, Laetitia ^a,b   Lemmer, Yolandy ^a,c   Kalombo, Lonji ^a   Katata, Lebogang ^a   Verschoor, Jan ^c   Swai, Hulda S ^a  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Biodistribution; Nanomedicine; Nanoparticles; PLGA; Toxicity

Indexed keywords

BALB/C MICE; BIODISTRIBUTIONS; CELL VIABILITY; DRUG DELIVERY SYSTEM; FUMED SILICA PARTICLES; FUMED SILICAS; IN-VITRO; IN-VIVO; MEAN PERCENTAGE; NANO METER RANGE; NANOMEDICINES; ORAL ADMINISTRATION; PARTICLE ACCUMULATION; PATHOLOGICAL CHANGES; PHYSICOCHEMICAL PROPERTY; PLGA; PLGA NANOPARTICLES; POLY-LACTIDE-CO-GLYCOLIDE; SIZE RANGES; SURFACE MODIFICATION; SYNTHETIC POLYMERS; TISSUE DAMAGE; TISSUE DISTRIBUTIONS; TOXIC EFFECT; ZINC OXIDE PARTICLES;

ASSAYS; DRUG DELIVERY; INDUSTRIAL POISONS; INDUSTRY; IRON OXIDES; LIVER; MEDICAL NANOTECHNOLOGY; SILICA; TERNARY SYSTEMS; TISSUE; TOXICITY; ZINC; ZINC OXIDE;

NANOPARTICLES;

FERROUS OXIDE; IRON DERIVATIVE; POLYGLACTIN; SILICON DIOXIDE; UNCLASSIFIED DRUG; ZINC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY; LIVER; LUNG; MOUSE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; SPLEEN; TISSUE DISTRIBUTION; TISSUE INJURY;

ANIMALS; CACO-2 CELLS; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYGLYCOLIC ACID;

MUS;

EID: 77957120419     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.02.002     Document Type: Article

References (22)

1. Magenheim B., Benita S. Nanoparticle characterization:a comprehensive physicochemical approach. S T P Pharm Sci 1991, 1:221-241.
2. Duncan R. Nanomedicine gets clinical. Materials Today 2005, 8:16-17.
3. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
4. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
5. Stone V., Donaldson K. Nanotoxicology: signs of stress. Nat Nanotechnol 2006, 1:23-24.
6. Li N., Xia T., Nel A.E. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008, 44:1689-1699.
7. Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Particle Fibre Toxicol 2005, 2:8-43.
8. McNeil S.E. Nanotechnology for the biologist. J Leukocyte Biol 2005, 78:585-594.
9. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995, 125:91-97.
10. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996, 13:1838-1845.
11. Wilkinson JM Roadmapping medical devices. Medical Device Link 2006, 6:1-90. Ref Type: Electronic Citation. Available at:. http://www.devicelink.com/mdt/archive/06/06/014.html.
12. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. In situ blood brain barrier transport of nanoparticles. Pharm Res 2003, 20:1772-1778.
13. Lamprecht A., Ubrich N., Hombreiro Perez M., Lehr C.M., Hoffman M., Maincent P. Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 1999, 184:97-105.
14. Brunauer S., Emmett P.H., Teller E. Adsorption of gases in multimolecular layers. J Am Chem Soc 1938, 60:309-319.
15. Merget R., Bauer T., Küpper H., Philippou S., Bauer H., Breitstadt R., et al. Health hazards due to the inhalation of amorphous silica. Arch Toxicol 2002, 75:625-634.
16. Vergoni A.V., Tosi G., Tacchi R., Vandelli M.A., Bertolini A., Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed Nanotechnol Biol Med 2009, 5:369-377.
17. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007, 122:1-9.
18. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
19. Campbell MK Biochemistry 1995, 365-384. Saunders College Publishing, Philadelphia.
20. Lockman P.R., Mumper R.J., Khan A., Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002, 28:1-13.
21. Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995, 17:31-48.
22. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995, 16:141-155.